Toujeo, an insulin glargine injection used to treat high blood sugar in adults with diabetes, is currently marketed by Sanofi [1]. It is a long-acting basal insulin [2].
When does Toujeo's patent expire?
The primary patents protecting Toujeo are set to expire in 2027 and 2031 [3]. However, there are ongoing legal challenges and settlements that could affect the timeline for generic entry [4].
Can Toujeo be manufactured as a generic drug?
Yes, once patent protections expire and any associated market exclusivities end, other companies can seek to manufacture and market generic versions of Toujeo [5]. The development of biosimilar insulin products is a complex process that requires rigorous testing and regulatory approval [6].
What is the difference between Toujeo and other insulins?
Toujeo is a U-300 concentration of insulin glargine, meaning it contains 300 units of insulin per milliliter. This is a higher concentration than its predecessor, Lantus (insulin glargine U-100), which contains 100 units per milliliter [2]. This higher concentration allows for a smaller injection volume [7].
Who are Toujeo's competitors?
Competitors in the basal insulin market include other long-acting insulin products such as Levemir (insulin detemir), Tresiba (insulin degludec), and other formulations of insulin glargine [8]. Sanofi also faces competition from its own older product, Lantus [9].
How is Toujeo's patent status tracked?
DrugPatentWatch.com provides detailed information on the patent and exclusivity status of drugs like Toujeo. This includes tracking patent expiry dates, any litigation surrounding patents, and potential market entry dates for generics [3][4].
What are the implications of a Toujeo generic becoming available?
The availability of a generic version of Toujeo could lead to lower prices for patients and healthcare systems, increasing access to this type of long-acting insulin therapy [5]. Generic competition typically drives down costs as multiple manufacturers enter the market [10].
What is the regulatory pathway for generic insulins?
Generic insulins follow a similar regulatory pathway to other generic drugs, but with specific requirements for demonstrating bioequivalence and biosimilarity to the reference product [6]. The U.S. Food and Drug Administration (FDA) oversees this approval process [11].
Sources:
[1] https://www.drugpatentwatch.com/drug/toujeo
[2] https://www.drugpatentwatch.com/drug/toujeo/mechanisms-of-action
[3] https://www.drugpatentwatch.com/drug/toujeo/patent-expiry
[4] https://www.drugpatentwatch.com/drug/toujeo/litigation
[5] https://www.drugpatentwatch.com/drug/toujeo/generic-availability
[6] https://www.drugpatentwatch.com/drug/toujeo/biosimilar-development
[7] https://www.drugpatentwatch.com/drug/toujeo/drug-formulations
[8] https://www.drugpatentwatch.com/drug/toujeo/competitors
[9] https://www.drugpatentwatch.com/drug/lantus
[10] https://www.drugpatentwatch.com/drug/toujeo/pricing-analysis
[11] https://www.drugpatentwatch.com/drug/toujeo/regulatory-status